Latest News

A reflection from HOPA 2026 explores medical misinformation and how oncology pharmacists can strengthen trust and guide evidence-based patient care.

frontMIND phase 3 trial data show tafasitamab plus lenalidomide with R-CHOP boosts PFS and has manageable safety in high-risk newly diagnosed DLBCL.

Skin Cancer Awareness Month in May spotlights oncology pharmacists driving prevention, innovative care, and supply-chain resilience built on patient trust.

Although polypharmacy is common in older adults and may increase the risk of adverse events and drug-drug interactions, statin therapy may continue to provide benefit in patients older than 75 years.

Time to next treatment (TTNT) is an emerging real-world end point in CAR T-cell therapy that reflects treatment durability, clinical outcomes, and health care system factors beyond traditional efficacy measures.

The misinformation is rampant, the adverse effect expectations are wildly off, and the patient psychology is complex.

Temperature differences between exhaled air and ambient environments significantly affect how respiratory aerosols disperse.

Chai Discovery’s collaboration with Eli Lilly highlights the growing role of AI in biologics discovery, leveraging generative AI models to accelerate design and optimization of novel therapeutic proteins and antibodies.

Although evidence supports safety of apixaban and rivaroxaban relative to warfarin, researchers have not directly compared their bleeding risk until last year.

Gonzelez describes advances in Alzheimer disease diagnostics and disease-modifying therapies and highlights the critical role pharmacists play in medication management, caregiver education, and improving treatment access.

Giants of MS is one of the field’s most prestigious honors, awarded at the 2026 Consortium for MS Centers (CMSC) 2026 Annual Meeting.

A landmark joint guideline on cardiovascular-kidney-metabolic syndrome offers clinicians a comprehensive, stage-based road map for screening, prevention, and treatment of an increasingly prevalent interconnected condition.

High-dose oral semaglutide pills boost A1C control and double-digit weight loss in diabetes and obesity trials, offering injectable-level results with daily convenience.

A post hoc analysis of the AT HOME-HF trial found lower hospitalization rates and longer time to admission among patients with diabetes treated with subcutaneous furosemide compared with usual care.

Patients deserve more than marketing. They deserve context.

Infection following CAR T-cell therapy is a common and clinically significant complication driven by prolonged immune dysregulation, cytopenias, and hypogammaglobulinemia, requiring phase-based risk awareness and proactive preventive management across the treatment continuum.

Alongside medication-specific counseling points, pharmacists can emphasize the importance of a therapeutic home environment.

The Centers for Medicare & Medicaid Services Innovation Center was born to create positive disruption to the financing and delivery of care. Its latest program may be the most likely to succeed (or fail).

Cannabinoids may offer modest, condition-specific analgesic benefits as adjunctive therapy in select chronic pain populations, but current evidence supports a limited role due to inconsistent efficacy, heterogeneity in studies, and safety and pharmacologic concerns.

At Duke Neurological Disorders Clinic, Jenelle Hall Montgomery, PharmD, BCACP, CPP, isn’t just advising on medications—she’s prescribing them, switching them, and managing the full arc of a patient’s therapy.

Vertanical's investigational cannabis-derived therapy VER-01 received FDA breakthrough therapy designation after positive phase 3 data demonstrated significant pain reduction and improved tolerability in patients with chronic low back pain.